Overview of Pediatric Drug Development. Dianne Murphy, MD Director Office of Counterterrorism and Pediatric Drug Development Center for Drug Evaluation and Research February 2, 2004. Goals.
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
Dianne Murphy, MD
Office of Counterterrorism and Pediatric Drug Development
Center for Drug Evaluation and Research
February 2, 2004
Losartan1-Year Post-ExclusivityReporting of Adverse Events
Tracking Cancer Risk among Children with Atopic Dermatitis who are treated with Topical Calcineurin Inhibitors
1- Pharmacokinetics are more variable than
2-Adverse reactions that are pediatric specific are being defined
3-Trial designs are being modified as we learn from submitted studies
4-Ethical issues have to be reassessed from the pediatric perspective
* from ICH E-11